VBL Therapeutics to Report Third Quarter 2015 Financial Results on November 12

TEL AVIV, Israel, Nov. 4, 2015 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq:VBLT), a clinical-stage biopharmaceutical company committed to the discovery, development and commercialization of first-in-class treatments for cancer, today announced that it will host a conference call and live audio webcast on Thursday, November 12, 2015 at 8:30 a.m. Eastern Time to report third quarter 2015 financial results.

Thursday, November 12th @ 8:30am Eastern Time
Domestic: 888-556-4997
International: 719-325-2215
Conference ID: 8496357
Webcast: http://edge.media-server.com/m/p/9hxy4fgd
Replays, available through November 26th:
Toll Free: 877-870-5176
International: 858-384-5517
Conference ID: 8496357

About VBL

Vascular Biogenics Ltd., operating as VBL Therapeutics, is a late-stage clinical biopharmaceutical company focused on the discovery, development and commercialization of first-in-class treatments for cancer. The Company's lead oncology product candidate, VB-111, is a gene-based biologic that is initially being developed for recurrent glioblastoma, or rGBM, an aggressive form of brain cancer. VB-111 has received orphan drug designation in both the United States and Europe and was granted Fast Track designation by the FDA for prolongation of survival in patients with glioblastoma that has recurred following treatment with standard chemotherapy and radiation. VBL Therapeutics' pivotal Phase 3 GLOBE trial of VB-111 in rGBM is ongoing under a special protocol assessment granted by the FDA.

CONTACT: INVESTOR CONTACT: Michael Rice, Founding Partner LifeSci Advisors, LLC 646-597-6979

Source: VBL Therapeutics